Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: Results of the DYSlipidemia International Study (DYSIS)

Atherosclerosis

Volumn 235, Issue 2, 2014, Pages 463-469

  Zhao, Shuiping ^a   Wang, Yongjun ^b,i   Mu, Yiming ^c   Yu, Bilian ^c   Ye, Ping ^c   Yan, Xiaowei ^d   Li, Zhanquan ^e   Wei, Yidong ^f   Ambegaonakr, Baishaili M ^g   Hu, Dayi ^h   Er, Bu Ai Jia ⁱ   Guiwen, Cao ⁱ   Buxing, Chen ⁱ   Hong, Chen ⁱ   Jin, Chen ⁱ   Jing, Chen ⁱ   Liefeng, Chen ⁱ   Min, Chen ⁱ   Qiong, Chen ⁱ   Shaoliang, Chen ⁱ   Tielong, Chen ⁱ   Xiaofei, Chen ⁱ   Xiaohong, Chen ⁱ   You, Chen ⁱ   Guoli, Cheng ⁱ   Mei, Cheng ⁱ   Hongliang, Cong ⁱ   Qin, Cui ⁱ   Shiwei, Cui ⁱ   Yong, Cui ⁱ   Shudong, Dai ⁱ   Henghua, Dai ⁱ   Xiaomei, Deng ⁱ   Yirong, Di ⁱ   Xiaoyan, Ding ⁱ   Birong, Dong ⁱ   Yumei, Dong ⁱ   Yugang, Dong ⁱ   Ping, Du ⁱ   Lei, Duan ⁱ   Limei, Fan ⁱ   Ningyuan, Fang ⁱ   Lixia, Fei ⁱ   Lie, Feng ⁱ   Jun, Ge ⁱ   GeWeihong, ⁱ   Hongmin, Guo ⁱ   Minxia, Guo ⁱ   Qinghua, Han ⁱ   Fengchang, He ⁱ   Dayi, Hu ⁱ   Lingzhi, Hu ⁱ   Xueqiang, Hu ⁱ   Yaojun, Hu ⁱ   Yiming, Hu ⁱ   Zhiping, Hu ⁱ   Fei, Hua ⁱ   Qi, Hua ⁱ   Dejia, Huang ⁱ   Gewen, Huang ⁱ   Hongman, Huang ⁱ   Liming, Huang ⁱ   Qiong, Huang ⁱ   Ruowen, Huang ⁱ   Taifu, Huang ⁱ   Bin, Jiang ⁱ   Kai, Jiao ⁱ   Hui, Jin ⁱ   Huigen, Jin ⁱ   Jinsong, Kuang ⁱ   Bao, Li ⁱ   Chengjiang, Li ⁱ   Hongjuan, Li ⁱ   Li Jun, Xinjiang ⁱ   Li Jun, Jiangsu ⁱ   Nanfang, Li ⁱ   Qifu, Li ⁱ   Qiang, Li ⁱ   Xin, Li ⁱ   Xueyou, Li ⁱ   Yanbing, Li ⁱ   Yanping, Li ⁱ   Yansheng, Li ⁱ   Yong, Li ⁱ   Yuling, Li ⁱ   Zhanquan, Li ⁱ   Zhengfang, Li ⁱ   Li, Liang ⁱ   Yongxue, Liang ⁱ   Zerong, Liang ⁱ   Yuhua, Liao ⁱ   Fan, Liu ⁱ   Hong, Liu ⁱ   Hui, Liu ⁱ   Minling, Liu ⁱ   Qiang, Liu ⁱ   Qingsong, Liu ⁱ   Shaokui, Liu ⁱ   Weidong, Liu ⁱ   Xueping, Liu ⁱ   Xinjian, Lu ⁱ   Benyan, Luo ⁱ   Shaonian, Luo ⁱ   Suxin, Luo ⁱ   Hong, Lv ⁱ   LvYun, ⁱ   Aiqun, Ma ⁱ   Jianhua, Ma ⁱ   Qiang, Ma ⁱ   Yan, Ma ⁱ   Changsheng, Ma ⁱ   Yide, Miao ⁱ   Yiming, Mu ⁱ   NieXiaoli, ⁱ   NiuXiaoyuan, ⁱ   Hongtao, Pan ⁱ   Mingkang, Pan ⁱ   Qiaoqing, Peng ⁱ   Huifen, Qian ⁱ   Qiumin, Qu ⁱ   Lijie, Qu ⁱ   Liqun, Ren ⁱ   Jingshan, Shao ⁱ   Qiang, Se ⁱ   Jing, Huang ⁱ   Xiuyun, Shen ⁱ   Yongquan, Shi ⁱ   Liangyi, Si ⁱ   Zhi, Song ⁱ   Zhiyuan, Song ⁱ   Yufeng, Sun ⁱ   Chunyan, Tan ⁱ   TengXiaochun, ⁱ   Haoming, Tian ⁱ   Wenhua, Tian ⁱ   Qinwei, Tong ⁱ   TuQiuyun, ⁱ   Keying, Wang ⁱ   Aihong, Wang ⁱ   Chaohui, Wang ⁱ   Chunning, Wang ⁱ   Dezhao, Wang ⁱ   Guixia, Wang ⁱ   Hanqiao, Wang ⁱ   Jianan, Wang ⁱ   Jianjun, Wang ⁱ   Lan, Wang ⁱ   Xiaoming, Wang ⁱ   Yaping, Wang ⁱ   Yangwei, Wang ⁱ   Meifang, Wei ⁱ   Yidong, Wei ⁱ   Hongyun, Wu ⁱ   Chun, Wu ⁱ   Dongmei, Wu ⁱ   Jiang, Wu ⁱ   Jun, Wu ⁱ   Xiaolin, Wu ⁱ   Zonggui, Wu ⁱ   XiGuangxia, ⁱ   Yi, Xiang ⁱ   Qian, Xiao ⁱ   Xiaoping, Xing ⁱ   Yulong, Xing ⁱ   Anding, Xu ⁱ   Yuanming, Xue ⁱ   Chuanzhu, Yan ⁱ   Tao, Yan ⁱ   Xiaowei, Yan ⁱ   Gangyi, Yang ⁱ   Jian, Yang ⁱ   Xiaosu, Yang Wangpingm Yang ⁱ   Xinchun, Yang ⁱ   Yifang, Yang ⁱ   Yu, Yang ⁱ   Mingyu, Yao ⁱ   Min, Ye ⁱ   Ping, Ye ⁱ   Bo, Yu ⁱ   Jiangyi, Yu ⁱ   Jinming, Yu ⁱ   Yan, Yu ⁱ   Ling, Zeng ⁱ   Longyi, Zeng ⁱ   Xiaoyun, Zeng ⁱ   Baorong, Zhang ⁱ   Bei, Zhang ⁱ   Chaoxin, Zhang ⁱ   Xuelian, Zhang ⁱ   Dadong, Zhang ⁱ   Dongping, Zhang ⁱ   Fuchun, Zhang ⁱ   Hong, Zhang ⁱ   Huifang, Zhang ⁱ   Liping, Zhang ⁱ   Liyang, Zhang ⁱ   Rufu, Zhang ⁱ   Saidan, Zhang ⁱ   Weijuan, Zhang ⁱ   Dong, Zhao ⁱ   Gang, Zhao ⁱ   Shuiping, Zhao ⁱ   Xiuxin, Zhao ⁱ   Qiangsun, Zheng ⁱ   Yang, Zheng ⁱ   Xiaohui, Zhou ⁱ   Yali, Zhou ⁱ   Yujie, Zhou ⁱ   Yi, Zhu ⁱ   Yulan, Zhu ⁱ   Xiangping, Zou ⁱ   more..

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^e The People's Hospital of Liaoning Province   (China)

^f TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

^g MERCK RESEARCH LABORATORIES   (United States)

^h PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

ⁱ NONE

Author keywords

Cardiovascular diseases; Dyslipidaemia; LDL cholesterol; Lipid lowering agents; Non HDL cholesterol; Statin

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; XUEZHIKANG; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHINA; CLINICAL EXAMINATION; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HIGH RISK PATIENT; HUMAN; LIPID ANALYSIS; LIPID BLOOD LEVEL; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PREDICTOR VARIABLE; PREVALENCE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; MIDDLE AGED;

AGED; CARDIOVASCULAR DISEASES; CHINA; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS, HDL; MIDDLE AGED; PREVALENCE; TRIGLYCERIDES;

EID: 84905822472     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.05.916     Document Type: Article

References (29)

1. He J., Gu D., Reynolds K., Wu X., Duan X., Yao C., et al. Major causes of death among men and women in China. N Engl J Med 2005, 353:1124-1134.
2. Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
3. Yang W., Xiao J., Yang Z., Ji L., Jia W., Weng J., et al. Serum lipids and lipoproteins in Chinese men and women. Circulation 2012, 125:2212-2221.
4. American Diabetes Association (ADA) Dyslipidemia management in adults with diabetes. Diabetes Care 2004, 27(90001):S68-S71.
5. Snow V., Aronson M.D., Hornbake E.R., Mottur-Pilson C., Weiss K.B. Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American college of physicians. Ann Intern Med 2004, 140:644-649.
6. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977, 62:707-714.
7. Sarwar N., Danesh J., Eiriksdottir G., Sigurdsson G., Wareham N., Bingham S., et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 western prospective studies. Circulation 2007, 115:450-458.
8. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
9. Fruchart J.C., Sacks F.M., Hermans M.P., Assmann G., Brown W.V., Ceska R., et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res 2008, 5:319-335.
10. Expert Panel on Detection E Treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAm Med Assoc 2001, 285:2486-2497.
11. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z., Catapano A.L., et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32:1769-1818.
12. National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
13. Hu D.Y., Ding R.J. Guidelines for management of adult dyslipidemia in China. Zhonghua Xin Xue Guan Bing Za Zhi 2007, 35:390-410.
14. Yu B.L., Zhao S.P., Peng D.Q., Huo Y., Hu L. Acomparison of non-HDL and LDL cholesterol goal attainment in the CHILLAS trial. Int J Cardiol 2013, 9(168):4340-4342.
15. Current Status in Clinical Control of Hypercholesterolemia in China Research Group Amulti-center study of current status on clinical control of hypercholesterolemia in China: success rate and related factors. Zhonghua Xin Xue Guan Bing Za Zhi 2002, 30:109-114.
16. Wu Y.F. The second multi-center survey of dyslipidemia management in China: goal attainment rate and related factors. Zhonghua Xin Xue Guan Bing Za Zhi 2007, 35:420-427.
17. Gitt A.K., Drexel H., Feely J., Ferrières J., Gonzalez-Juanatey J.R., Thomsen K.K., et al. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prev Cardiol 2012, 19:221-230.
18. Goodman S.G., Langer A., Bastien N.R., McPherson R., Francis G.A., Genest J.J., et al. Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS). Can J Cardiol 2010, 26:e330-e335.
19. Yusuf S., Islam S., Chow C.K., Rangarajan S., Dagenais G., Diaz R., et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011, 378:1231-1243.
20. Gitt A.K., Jünger C., Smolka W., Bestehorn K. Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany. Clin Res Cardiol 2010, 99:723-733.
21. Hwang J.Y., Jung C.H., Lee W.J., Park C.Y., Kim S.R., Yoon K.H., et al. Low density lipoprotein cholesterol target goal attainment rate and physician perceptions about target goal achievement in Korean patients with diabetes. Diabetes Metab J 2011, 35:628-636.
22. Kennedy A.G., MacLean C.D., Littenberg B., Ades P.A., Pinckney R.G. The challenge of achieving national cholesterol goals in patients with diabetes. Diabetes Care 2005, 28:1029-1034.
23. Yan A.T., Yan R.T., Tan M., Hackam D.G., Leblanc K.L., Kertland H., et al. Vascular Protection (VP) and guidelines oriented approach to lipid lowering (GOALL) registries investigators. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med 2006, 119:676-683.
24. Teoh H., Mendelsohn A.A., Goodman S.G., Jaffer S., Chen R.Y., Tjia S., et al. Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease. Am J Cardiol 2009, 104:798-804.
25. Maron D.J., Hartigan P.M., Neff D.R., Weintraub W.S. W.E. Boden; COURAGE Trial Investigators. Impact of adding ezetimibe to statin to achieve low-density lipoprotein cholesterol goal (from the clinical outcomes utilizing revascularization and aggressive drug evaluation [COURAGE] trial). Am J Cardiol 2013, 111:1557-1562.
26. Chin C.W., Gao F., Le T., Tan R. Lipid goal attainment and prescription behavior in asian patients with acute coronary syndromes: experience from a tertiary hospital. Clin Med Insights Cardiol 2013, 7:51-57.
27. Gao F., Zhou Y.J., Hu D.Y., Zhao Y.X., Liu Y.Y., Wang Z.J., et al. Contemporary management and attainment of cholesterol targets for patients with dyslipidemia in China. PLoS One 2013, 8. e47681.
28. Leiter L.A., Lundman P., da Silva P.M., Drexel H., Jünger C., Gitt A.K., et al. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet Med 2011, 28:1343-1351.
29. Robinson J.G., Want S., Smith B.J., Jacobson T.A. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease. JAm Coll Cardiol 2009, 53:316-322.